Menu

FDA Study Halted After Jane Goodall Objects

The primatologist had written to the agency that the trial, which involved observing the effects of nicotine addiction in squirrel monkeys, was “cruel and unnecessary.”

Sep 26, 2017
Bob Grant

WIKIMEDIA, BORIS23The US Food and Drug Administration (FDA) has paused a study of nicotine addiction in squirrel monkeys that primatologist Jane Goodall objected to. She wrote a letter—in which she called the research “horrific”—to FDA Commissioner Scott Gottlieb. Although Gottlieb communicated with Goodall, an FDA spokesman tells The Scientist that the agency's decision to stop the study was independent of her plea. The letter from Goodall, an outspoken animal rights advocate, was posted on the website of the White Coat Waste (WCW) Project, an organization that seeks to stop animal research funded by US taxpayers, earlier this month (September 7).

According to the Washington Post, Gottlieb responded to Goodall on Monday (September 25), saying that he would temporarily suspend the three-year-old study, which FDA researchers are conducting at the agency’s National Center for Toxicological Research in Arkansas. The FDA commissioner reportedly assured Goodall that he made the decision “after learning of concerns related to the study you referenced,” and said that he was dispatching primate experts to the Arkansas facility “to evaluate the safety and well-being of the monkeys and to understand whether there are additional precautions needed.”

In her letter, Goodall took issue with the fact that juvenile monkeys were being implanted with devices that delivered nicotine directly into their systems and then taught to press a lever that dosed them with the drug. She also claimed that the animals were isolated in cages for “nearly three years,” and referenced video footage that exists documenting the conditions. “To continue performing nicotine experiments on monkeys when the results of smoking are well-known in humans—whose smoking habits can still be studied directly—is shameful,” Goodall wrote. “I’m sure that most Americans would be horrified to learn their tax dollars are paying for this abuse.”

The WCW apparently asked Goodall to write the letter after obtaining information about the research, which involved 12 adult and 12 adolescent monkeys, via the Freedom of Information Act.

While the WCW applauded the FDA’s decision to halt the trial, others in the scientific community expressed their displeasure with Goodall’s assertions. An editor writing last week (September 20) on Speaking of Research, a website for an animal research advocacy group, decries Goodall’s lack of “relevant credentials,” her propagation of “factual inaccuracies” in her letter describing the squirrel monkey research, and her “sweeping assumptions.”

“Studies such as those conducted by the FDA in animals, including monkeys, will teach us how these new delivery methods affect the brain and body, which will in turn lead to recommendations for regulation of these products and potential treatments for addiction,” the editor writes. “Despite these life-saving benefits, Goodall and WCW call for an end to this line of research in their letter.”

Correction (September 27): We have updated the first paragraph to indicate that Goodall’s letter did not influence Gottlieb’s decision to stop the study. The Scientist regrets the error.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.